Viloxazine Hydrochloride 100 mg, 150 mg, 200 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 100 mg, 150 mg, 200 mg

Reference Brands: Qelbree (USA)

Category: Neurology

Viloxazine extended-release capsules (100–200 mg) are a non-stimulant treatment for ADHD in children and adults, acting mainly as a noradrenaline reuptake inhibitor. It is not a controlled substance. It is made by Supernus as Qelbree. Supply is through authorised distribution or named-patient import; ask us which route fits your country.

Product Description:

Viloxazine is a centrally acting selective norepinephrine reuptake inhibitor that is marketed under the brand name Qelbree, among others, for the treatment of attention deficit hyperactivity disorder (ADHD) in both children and adults. ADHD is a neurodevelopmental condition characterized by inattention, hyperactivity, and impulsivity, which can significantly impact academic performance, work productivity, and social functioning.

Viloxazine has a long clinical history and was originally marketed for nearly three decades as an antidepressant for the treatment of depressive disorders before its discontinuation for that indication. Based on its mechanism of action and effects on norepinephrine signaling in the brain, it was later repurposed and developed for the management of ADHD. In its current approved use, viloxazine is administered orally as an extended-release formulation, allowing for sustained drug release and once-daily dosing.

The extended-release form is designed to provide steady symptom control throughout the day while offering a non-stimulant alternative for patients who may not tolerate or respond well to stimulant medications. Although clinical evidence suggests that viloxazine may be less effective in reducing ADHD symptoms compared to stimulant therapies such as methylphenidate, it remains a valuable treatment option for selected patients seeking non-stimulant management of ADHD.